Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 2/20 | 0.53 |
| ▸ | MMP3 | P08254 | 2/20 | 0.53 |
| ▸ | MMP9 | P14780 | 2/20 | 0.53 |
| ▸ | CTSS | P25774 | 3/20 | 0.50 |
| ▸ | CTSK | P43235 | 3/20 | 0.50 |
| ▸ | CTSL | P07711 | 5/20 | 0.49 |
| ▸ | CTSB | P07858 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 2/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18941938 | 0.94 | CTSS (0.57) | MMP1MMP3MMP9CTSSCTSK | |
| SCHEMBL28198598 | 0.89 | CTSS (0.57) | CTSSCTSKCTSLCTSBPOLB | |
| SCHEMBL28198599 | 0.89 | CTSS (0.57) | CTSSCTSKCTSLCTSBPOLB | |
| SCHEMBL10857658 | 0.89 | CTSS (0.57) | CTSSCTSKCTSLCTSBPOLB | |
| SCHEMBL20825233 | 0.89 | REN (0.58) | MMP1MMP3MMP9CTSSCTSK | |
| SCHEMBL17452275 | 0.87 | CTSS (0.59) | MMP1MMP3MMP9CTSSCTSK | |
| SCHEMBL17452230 | 0.85 | CTSK (0.53) | MMP1MMP3MMP9CTSSCTSK | |
| SCHEMBL27487988 | 0.85 | CTSS (0.65) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL27487987 | 0.85 | CTSS (0.65) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL3821800 | 0.85 | CTSS (0.65) | CTSSCTSKCTSLCTSBACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787482-B2 | Epoxyketone compounds for enzyme inhibition | Centrax International Inc. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20200087343-A1 | EPOXYKETONE COMPOUNDS FOR ENZYME INHIBITION | CENTRAX INTERNATIONAL, INC. (US) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787482-B2 | Epoxyketone compounds for enzyme inhibition | PSMD10, PSMC1, PSMB10 | MMP1 1886/4885MMP3 2080/4885MMP9 1939/4885 |
| US-20200087343-A1 | EPOXYKETONE COMPOUNDS FOR ENZYME INHIBITION | PSMD10, PSMC1, PSMB10 | MMP1 1886/4885MMP3 2080/4885MMP9 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.